Advertisement

ART-Free Remission in an HIV-Infected Infant with Very Early Treatment

Summary and Comment |
November 5, 2013

ART-Free Remission in an HIV-Infected Infant with Very Early Treatment

  1. Timothy J. Henrich, MD

At last, what we have all been waiting for — the formal report on the “Mississippi child”

  1. Timothy J. Henrich, MD

Recent evidence suggests that treatment very early in acute HIV infection limits seeding of viral reservoirs and — in some instances — might enable virologic control, even after discontinuation of antiretroviral therapy (ART). However, the effects of very early treatment after in utero or perinatal HIV acquisition are not well understood.

Researchers now describe the clinical course and laboratory findings of the “Mississippi child,” who — because of high-risk exposure — was started on combination ART 30 hours after birth. Testing during labor had revealed HIV infection in the mother; delivery had occurred before administration of antiretroviral prophylaxis. The mother had a relatively low viral load (2423 copies/mL).

At approximately 30 hours after birth, the child had detectable HIV DNA in peripheral blood mononuclear cells and a viral load of 19,812 copies/mL. After ART initiation, the viral load declined, as typically occurs with effective treatment of established infection; 28 days later, it was below the level of detection by commercial assay. ART was discontinued at age 18 months, according to the mother, and commercial viral load and antibody testing remained negative 12 months thereafter.

Sensitive testing was conducted to evaluate the persistence of HIV infection. Low-level, residual viremia was detected in plasma at 24 months of age but not at 26 months; co-culture assays of CD4 cells at 24 months did not yield replication-competent virus. However, low levels of HIV DNA were quantified just at the detection threshold of a sensitive assay at 24 and 26 months. Interestingly, no HIV DNA was found in resting CD4 cells, the best-described long-term HIV reservoir.

Comment

The Mississippi child is different from adults who experience antiretroviral therapy–free virologic control after very early treatment initiation, because only traces of viral genetic material remained after treatment interruption. Nonetheless, this provocative study adds to the growing body of literature suggesting that early ART may be beneficial in limiting the seeding of viral reservoirs. It is possible that restricting reservoir seeding could lead to virologic control after ART cessation in certain individuals, but the durability of remission in this child remains to be determined. All eyes are eagerly watching.

Dr. Henrich is an Instructor in Medicine at Harvard Medical School and an Associate Physician at Brigham and Women's Hospital in Boston. He declares no conflicts of interest.

Citation(s):

Reader Comments (1)

MARILYN DOYLE Physician, Pediatric Subspecialty

I had the opportunity to start many infants on ART as soon as I knew they were infected and when in homes where strict adherence was applied many of the children had negative antibody and undetectable viral load . I never stopped the ART H

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement